Article Text

Download PDFPDF
Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis
  1. Emily Montague1,
  2. Kimberley Hockenhull1,
  3. Angela Lamarca1,
  4. Tamer Al-Sayed2 and
  5. Richard A Hubner1
  1. 1 Medical Oncology, Christie NHS Foundation Trust, Manchester, UK
  2. 2 Acute/Renal Medicine, Christie NHS Foundation Trust, Manchester, UK
  1. Correspondence to Dr Emily Montague, emily.montague{at}


Paraneoplastic glomerular disease is an increasingly well-recognised entity, and a wide range of both solid and haematological malignancies have been implicated. The most common glomerular disease associated with cancer is membranous nephropathy. Only a few case reports have described an association between neuroendocrine tumours (NETs) and glomerulonephritis and only one paediatric case in relation to minimal change disease. A 76-year-old woman with a well-differentiated duodenal NET presented with nephrotic syndrome and renal biopsy was suggestive of minimal change glomerulonephritis. Standard therapy with corticosteroids brought little benefit, but a dramatic improvement was seen following initiation of systemic anticancer therapy with lanreotide, a somatostatin analogue. Less than 1 month after initiation of lanreotide, the patient was no longer in a nephrotic state, and after a further 2 months of follow-up had shown no sign of relapse.

  • endocrine cancer
  • nephrotic syndrome
  • proteinurea
  • small intestine cancer

Statistics from


  • Contributors EM, KH and RAH contributed to the conception and design of the article. Drafting and data collection and analysis were done by EM. KH, RAH, AL and TA-S contributed to revisions and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.